Myeloma Treatments
The following is a listing of myeloma treatments associated with this tag.
All Treatments
View all treatments in development for myeloma patients around the US.
Verified
Tinostamustine
Tinostamustine (formerly EDO-S101) is a first-in-class fusion molecule combining vorinostat (a histone-deacetylase inhibitor) and bendamustine (an alkylating chemotherapy agent).
SparkCures Verified Accurate, up-to-date information. Learn more
Early Relapse Multiple Myeloma
The following is a listing of treatments in development for patients with multiple myeloma who have received one to two prior lines of therapy.
Verified
Tinostamustine
Tinostamustine (formerly EDO-S101) is a first-in-class fusion molecule combining vorinostat (a histone-deacetylase inhibitor) and bendamustine (an alkylating chemotherapy agent).
SparkCures Verified Accurate, up-to-date information. Learn more
Late Relapse Multiple Myeloma
The following is a listing of treatments in development for patients with multiple myeloma who have received three or more prior lines of therapy.
Verified
Tinostamustine
Tinostamustine (formerly EDO-S101) is a first-in-class fusion molecule combining vorinostat (a histone-deacetylase inhibitor) and bendamustine (an alkylating chemotherapy agent).
SparkCures Verified Accurate, up-to-date information. Learn more
Myeloma Clinical Trials
The following is a listing of myeloma clinical trials associated with this tag.
All Clinical Trials
View all active clinical trials around the US.
SparkCures Verified Accurate, up-to-date information. Learn more
A 2 Step Approach to Haploidentical Transplant Using Radiation-Based Reduced Intensity Conditioning
RADIATION-BASED REDUCED INTENSITY CONDITIONINGA Multi-Center, Phase 3, Randomized Trial of Matched Unrelated Donor (MUD) Versus HLA-Haploidentical Relate...
MISMATCHED RELATED VS. MATCHED UNRELATED DONORA Phase 1 Study of Adding Venetoclax to a Reduced Intensity Conditioning Regimen and to Maintenance in Comb...
VENETOCLAX IN PRE- AND POST-TRANSPLANT THERAPYA Phase 1/2 Multi-Center Trial of Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents ...
VORINOSTAT FOR GVHD PREVENTIONA Phase 1a/b Study to Evaluate the Safety & Tolerability of JSP191 in Combination With a Regimen of Low Dos...
JSP191 CONDITIONING REGIMENA Phase 1b/2 Study of the BCL-2 Inhibitor Venetoclax in Combination With Standard Intensive AML Induction/C...
VENETOCLAX W/ COMBINATION CHEMOTHERAPYA Phase 2 Study of Fludarabine, Cytarabine, Filgrastim-sndz,Gemtuzumab Ozogamicin and Idarubicin in Newly D...
GEMTUZUMAB AS PART OF CHEMOTHERAPYA Phase I Study of Intensity Modulated Total Marrow Irradiation (IMTMI) in Addition to Fludarabine/Melphala...
INTENSITY MODULATED TOTAL MARROW IRRADIATIONA Phase Ib Study of Oral Decitabine/Cedazuridine as Maintenance Therapy Following Allogeneic Hematopoietic ...
DECITABINE/CEDAZURIDINE AS MAINTENANCE THERAPYA Phase II Randomized Controlled Trial Comparing GVHD-Reduction Strategies for Allogeneic Peripheral Blood ...
GRAFT VERSUS HOST DISEASE-REDUCTION STRATEGIESA Phase II Randomized Study to Assess Outcomes With Treosulfan-Based Versus Clofarabine-Based Conditioning ...
TREOSULFAN VS. CLOFARABINE-BASED CONDITIONINGA Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Aza...
CLADRIBINE, CYTARABINE AND VENETOCLAX FOR HR-MDSA Phase II Study of the Efficacy and Pharmacogenomics of Cladribine-based Salvage Chemotherapy in Patients ...
CLADRIBINE BASED SALVAGE CHEMOTHERAPYA Pilot Study of Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination With Gemtuzumab Ozogamicin ...
CPX-351 PLUS GEMTUZUMAB OZOGAMICINA Pilot/Phase 1 Study of Immunosuppression-free Regulatory T-cell Graft-engineered Haploidentical Hematopoi...
IS-FREE TREG STEM CELL TRANSPLANTAllogeneic Hematopoietic Stem Cell Transplant for Patients With Mutations in GATA2 or the MonoMAC Syndrome
ALLO STEM CELL TRANSPLANT FOR GATA2 MUTATIONSAlpha/Beta TCD HCT in Patients With Inherited BMF Disorders
T CELL RECEPTOR DEPLETION IN STEM CELL TRANSPLANTAn Open-label, Non-randomized, Prospective Trial to Evaluate the Effect of Renal Function Impairment and Ra...
TREOSULFAN AND FLUDARABINE PRE-TRANSPLANTCardioprotection With Dexrazoxane in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS)...
HEART PROTECTION W/DEXRAZOXANE DURING CHEMOTHERAPYCD45RA Depleted Peripheral Stem Cell Addback for Patients at Risk for Viral or Fungal Infections Post TCRαβ...
ADDBACK OF DONOR CD45RA DEPLETED CELLSCord Blood Transplantation in Children and Young Adults With Hematologic Malignancies and Non-malignant Dis...
CORD BLOOD TRANSPLANTATION IN CHILDRENCytokine-Treated Veto Cells in Treating Participants With Hematologic Malignancies Following Stem Cell Tran...
CYTOKINE-TREATED VETO CELLS POST-TRANSPLANTFeasibility Study of CD34 Selection for GVHD Prophylaxis Using the Automated CliniMACS
GVHD PREVENTION USING CLINIMACSHaplo-identical Transplantation for Severe Aplastic Anemia, Hypo-plastic MDS and PNH Using Peripheral Blood...
POST-TRANSPLANT CYCLOPHOSPHAMIDEHigh Dose Ascorbic Acid (HDAA) in Patients With Plasma Cell Disorders
HIGH DOSE ASCORBIC ACID W/ MELPHALANHigh Dose Ascorbic Acid for Plasma Cell Disorders
HIGH-DOSE ASCORBIC ACIDLymphodepleting Chemotherapy With Fludarabine and Cyclophosphamide Prior to Infusion of CAR T Cell Therapy ...
CAR T IN PATIENTS WITH RENAL IMPAIRMENTMyeloablative Allogeneic Hematopoietic Stem Cell Transplant With Related or Unrelated Donor for Hematologic...
MYELOABLATIVE ALLO STEM CELL TRANSPLANTOptimized Cord Blood Transplantation for the Treatment of High-Risk Hematologic Malignancies in Adults and ...
OPTIMIZED CORD BLOOD TRANSPLANTPersonalized NK Cell Therapy After Chemotherapy and Cord Blood Transplant in Treating Patients With Myelody...
PERSONALIZED NATURAL KILLER CELL THERAPYPhase 1 Trial of Ivosidenib and FLAG Chemotherapy in Relapsed/Refractory IDH1+ Acute Myeloid Leukemia (AML)
IVOSIDENIB AND COMBINATION CHEMOTHERAPYPhase 1B Study of Venetoclax in Combination With Standard Intensive Chemotherapy With Daunorubicin Plus Cyt...
VENETOCLAX PLUS INTENSIVE CHEMOTHERAPYPhase I Study of Escalating Doses of Total Marrow and Lymphoid Irradiation (TMLI) Combined With Fludarabine...
TOTAL MARROW AND LYMPHOID IRRADIATIONPhase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymp...
CORD BLOOD-DERIVED NK CELLSPhase II Prospective Randomized Control Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating Wit...
CLADRIBINE WITH LOW-DOSE CYTARABINEPhase II Study of Cladribine Plus Idarubicin Plus Cytarabine (ARAC) in Patients With AML, HR MDS, or Myeloi...
CHEMOTHERAPY PLUS VENETOCLAXPhase II Study of Cladribine Plus Low Dose Cytarabine (LDAC) Induction Followed By Consolidation With Cladr...
CYTARABINE ALTERNATING WITH DECITABINEPhase II Study of Evaluating the Efficacy of Total Marrow and Lymphoid Irradiation (TMLI) as the Conditioni...
TOTAL MARROW AND LYMPHOID IRRADIATIONPhase II Study of Horse Anti-Thymocyte Globulin (hATG), Cyclosporine, Methylprednisolone, and GCSF (Filgras...
HORSE ANTI-THYMOCYTE GLOBULIN (HATG)Pilot Study of Daratumumab in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone (Dara-CyBorD...
DARATUMUMAB FOR PATIENTS WITH RENAL FAILUREPilot Study: Infusion of Off-the-Shelf Ex Vivo Expanded Cryopreserved Progenitor Cells (Dilanubicel) in the...
INFUSION OF EXPANDED CORD BLOOD CELLSPlacebo-Controlled and Randomized Phase 2 Trial of CMV-MVA Triplex Vaccination in HLA-Matched Related Stem ...
CMV-MVA TRIPLEX VACCINATIONPropylene Glycol-Free Melphalan HCl (EVOMELA®) in Combination With Fludarabine and Total Body Irradiation B...
EVOMELA® COMBINATION CONDITIONING THERAPYReduced Intensity, Partially HLA Mismatched Allogeneic BMT for Hematologic Malignancies Using Donors Other ...
PARTIALLY MISMATCHED STEM CELL TRANSPLANTSingle Center Pilot Study to Investigate the Efficacy of Adding Itacitinib to Post-Transplant Cyclophospham...
ITACITINIB FOR GVHD PREVENTIONTCR-αβ+ and CD19+ Depleted KIR/KIR Ligand-mismatched Haploidentical Hematopoietic Stem Cell Transplant and ...
TCRαβ+/CD19+ DEPLETED HAPLOIDENTICAL HSCTUmbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases
UCB TRANSPLANT WITH MYELOABLATIVE PREPVenetoclax in Combination With ASTX727, an All-ORal Therapy for Chronic Myelomonocytic Leukemia and Other M...
VENETOCLAX IN COMBINATION WITH ASTX727Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS
VENETOCLAX AS PART OF PRE-TRANSPLANT CHEMOTHERAPY
Untreated / Newly Diagnosed Multiple Myeloma
The following is a listing of clinical trials for patients with multiple myeloma who have been newly diagnosed or have not yet received treatment.
Lymphodepleting Chemotherapy With Fludarabine and Cyclophosphamide Prior to Infusion of CAR T Cell Therapy ...
CAR T IN PATIENTS WITH RENAL IMPAIRMENT
Early Relapse Multiple Myeloma
The following is a listing of clinical trials for patients with multiple myeloma who have received one to two prior lines of therapy.
SparkCures Verified Accurate, up-to-date information. Learn more
Cytokine-Treated Veto Cells in Treating Participants With Hematologic Malignancies Following Stem Cell Tran...
CYTOKINE-TREATED VETO CELLS POST-TRANSPLANTLymphodepleting Chemotherapy With Fludarabine and Cyclophosphamide Prior to Infusion of CAR T Cell Therapy ...
CAR T IN PATIENTS WITH RENAL IMPAIRMENTMyeloablative Allogeneic Hematopoietic Stem Cell Transplant With Related or Unrelated Donor for Hematologic...
MYELOABLATIVE ALLO STEM CELL TRANSPLANTPersonalized NK Cell Therapy After Chemotherapy and Cord Blood Transplant in Treating Patients With Myelody...
PERSONALIZED NATURAL KILLER CELL THERAPYUmbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases
UCB TRANSPLANT WITH MYELOABLATIVE PREP
Late Relapse Multiple Myeloma
The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.
Cytokine-Treated Veto Cells in Treating Participants With Hematologic Malignancies Following Stem Cell Tran...
CYTOKINE-TREATED VETO CELLS POST-TRANSPLANTHigh Dose Ascorbic Acid (HDAA) in Patients With Plasma Cell Disorders
HIGH DOSE ASCORBIC ACID W/ MELPHALANHigh Dose Ascorbic Acid for Plasma Cell Disorders
HIGH-DOSE ASCORBIC ACIDLymphodepleting Chemotherapy With Fludarabine and Cyclophosphamide Prior to Infusion of CAR T Cell Therapy ...
CAR T IN PATIENTS WITH RENAL IMPAIRMENTMyeloablative Allogeneic Hematopoietic Stem Cell Transplant With Related or Unrelated Donor for Hematologic...
MYELOABLATIVE ALLO STEM CELL TRANSPLANTPersonalized NK Cell Therapy After Chemotherapy and Cord Blood Transplant in Treating Patients With Myelody...
PERSONALIZED NATURAL KILLER CELL THERAPYUmbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases
UCB TRANSPLANT WITH MYELOABLATIVE PREP
Smoldering Myeloma
No active clinical trials
Monoclonal Gammopathy of Undetermined Significance (MGUS)
No active clinical trials